Penetration of nitroxoline in the prostatic parenchyma. Therapeutic trial (proceedings)
Dufour, A.; Bollack, C.
Journal d'Urologie et de Nephrologie 85(3): 207-212
1979
ISSN/ISBN: 0021-8200 PMID: 113556 Document Number: 3652
Nous avons traité plusieurs cas de prostatites aiguës par de la nitroxoline (*), confortés par son activité antibactérienne et sa bonne pénétration dans la glande prostatique.
Document emailed within 1 workday
Related Documents
Beurton, D.; Pascal, B.; Bronstein, M.; Lepage, T.; Ridoux, G.; Cukier, J. 1979: Medical treatment of ureteral calculi. Therapeutic trial with a synthetic anti-inflammatory agent in 97 patients (proceedings) Journal d'Urologie et de Nephrologie 85(3): 260-264Yu, H.J.; Chiu, T.Y.; Lai, M.K. 1995: Therapeutic effects of finasteride in benign prostatic hyperplasia: a randomized double-blind controlled trial Journal of the Formosan Medical Association 94(1-2): 37-41
Gratzke, P.; Kirby, R.S. 2000: Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability Fortschritte der Medizin. Originalien 118(Suppl 2): 83-92
Bergogne-Berezin, E.; Berthelot, G.; Muller-Serieys, C. 1987: Present status of nitroxoline Pathologie-Biologie 35(5 Part 2): 873-878
Deutsch, E. 1997: Therapeutic trial, clinical research and therapeutic freedom--legal boundaries Zeitschrift für Arztliche Fortbildung und Qualitatssicherung 91(7): 698-700; Discussion 701
Pelletier, C.; Prognon, P.; Latrache, H.; Villart, L.; Bourlioux, P. 1994: Microbiological consequences of chelation of bivalent metal cations by nitroxoline Pathologie-Biologie 42(5): 406-411
Cancet, B.; Amgar, A. 1987: In vitro antifungal activity of nitroxoline. Preliminary clinical results Pathologie-Biologie 35(5 Part 2): 879-881
Bogdanowicz, J.F.; Bentvelsen, F.M.; Oosterom, R.; Schroeder, F.H. 1991: Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia Scandinavian Journal of Urology and Nephrology. Supplementum 138: 97-103
Hohenfellner, R. 1978: Prostatic carcinoma. Therapeutic concept Die Medizinische Welt 29(31): 1189-1191
Isa Kroon, W.A.; Robles García, J.E. 1993: Therapeutic alternatives in benign prostatic hyperplasia Medicina Clinica 101(2): 64-66
Studer, U.E. 1988: Prognostic and therapeutic aspects of prostatic carcinoma Schweizerische Rundschau für Medizin Praxis 77(20): 545-550
Schulze, H.; Berges, R.; Paschold, K.; Senge, T. 1992: New conservative therapeutic approaches in benign prostatic hyperplasia Der Urologe. Ausg. a 31(1): 8-13
Bouffioux, C. 1974: Histological study of prostatic cancer. Prognostic and therapeutic value Journal d'Urologie et de Nephrologie 80(12 Part 2): 531-540
Glemain, P.; Coulange, C.; Billebaud, T.; Gattegno, B.; Muszynski, R.ël.; Loeb, G.ér. 2002: Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: the OCOS trial Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 12(3): 395-403; Discussion 404
Champault, G.; Bonnard, A.M.; Cauquil, J.; Patel, J.C. 1984: Medical treatment of prostatic adenoma. Controlled trial: PA 109 vs placebo in 110 patients Annales d'Urologie 18(6): 407-410
Yamanaka, H.; Shida, K. 1984: Pharmacology and metabolism of a new therapeutic drug for prostatic cancer "Estracyt" Gan to Kagaku Ryoho. Cancer and ChemoTherapy 11(3): 537-544
Virgili, G.; Mearini, E.; Sbarberi, L.; Camilli, P.; Costantini, E. 1986: Therapeutic efficacy of mepartricin in the medical treatment of prostatic hypertrophy Minerva Medica 77(20): 861-866
Tachev, S.; Petrov, P.; Simeonov, P. 1988: Therapeutic potentials of the preparation dibenziran in patients with prostatic adenoma Khirurgiia 41(4): 30-32
1991: Therapeutic advantages of droloxifene, a new antiestrogen, in breast cancer. Proceedings of a satellite symposium held during the 15th International Cancer Congress. Hamburg, F.R.G., August 18, 1990 American Journal of Clinical Oncology 14 Suppl. 2: S1-63
Debruyne, F.M.; Karthaus, H.F.; Schröder, F.H.; de Voogt, H.J.; de Jong, F.H.; Klijn, J.G. 1985: Results of a Dutch Phase Ii trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer Progress in Clinical and Biological Research 185a: 251-270